Allogene Therapeutics Inc (NASDAQ: ALLO) on Monday, plunged -6.16% from the previous trading day, before settling in for the closing price of $1.46. Within the past 52 weeks, ALLO’s price has moved between $0.86 and $3.78.
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.26%. The company achieved an average annual earnings per share of 29.47%. With a float of $159.44 million, this company’s outstanding shares have now reached $223.16 million.
Let’s determine the extent of company efficiency that accounts for 229 employees.
Allogene Therapeutics Inc (ALLO) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Allogene Therapeutics Inc is 29.05%, while institutional ownership is 50.57%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. In this transaction SVP, Chief Technical Officer of this company sold 786 shares at a rate of $1.22, taking the stock ownership to the 217,721 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 786 for $1.22, making the entire transaction worth $959.
Allogene Therapeutics Inc (ALLO) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.28 earnings per share (EPS) for the period topping the consensus outlook (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.61% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Allogene Therapeutics Inc (ALLO) is currently performing well based on its current performance indicators. A quick ratio of 8.19 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Looking closely at Allogene Therapeutics Inc (NASDAQ: ALLO), its last 5-days average volume was 2.49 million, which is a drop from its year-to-date volume of 3.92 million. As of the previous 9 days, the stock’s Stochastic %D was 81.52%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 54.66%, which indicates a significant decrease from 64.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0928 in the past 14 days, which was higher than the 0.0876 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2574, while its 200-day Moving Average is $1.3635. However, in the short run, Allogene Therapeutics Inc’s stock first resistance to watch stands at $1.4317. Second resistance stands at $1.4933. The third major resistance level sits at $1.5367. If the price goes on to break the first support level at $1.3267, it is likely to go to the next support level at $1.2833. Should the price break the second support level, the third support level stands at $1.2217.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
Market capitalization of the company is 307.88 million based on 224,730K outstanding shares. Right now, sales total 20 K and income totals -257,590 K. The company made 0 K in profit during its latest quarter, and -41,400 K in sales during its previous quarter.
